| D50 | Record linkage without patient identifiers: a proof of concept using laboratory and clinical data from South Africa's HIV program''''' | E-poster | Monitoring and evaluation of HIV cascade |
| C27 | Real-world utilization of F/TDF and F/TAF for HIV Pre-exposure Prophylaxis during the COVID-19 pandemic in the US, December 2019 ' June 2020 | On-demand oral abstract session | PrEP |
| A36 | Reactivity of plasma from HIV-infected pregnant women with recombinant Q β phages displaying the membrane proximal external region of HIV-1 envelope | E-poster | Novel vectors and strategies |
| D12 | Reaching males living with HIV though scale-up of index testing services: 8 countries in sub-Saharan Africa | E-poster | Uptake of HIV testing |
| B13 | Reaching HCV micro-elimination in HIV/HCV co-infected individuals in the Netherlands: exploring remaining barriers to HCV treatment | On-demand oral abstract session | Viral hepatitis C |
| C33 | Reaching for the "first 95": a cross-country analysis of HIV self-testing in 177,572 people in nine countries in sub-Saharan Africa | On-demand oral abstract session | HIV self-testing |
| D97 | 'Reaching adolescents where they are': Innovative recruitment strategies for PrEP enrolment of adolescent´s key population in Brazil | E-poster | Pre-exposure prophylaxis |
| D34 | Reaching absent and refusing individuals during home-based HIV testing through self-testing: a costing perspective | E-poster | National financing initiatives and country ownership |
| D33 | RAPID-VL intervention improves viral load ordering, results turnaround time and viral suppression: a cluster randomized trial in HIV clinics in Uganda | Oral abstract session with live Q&A | Scale up of viral load monitoring |
| C27 | Rapid scale-up of oral pre-exposure prophylaxis (PrEP) for key populations: experience from the PEPFAR/USAID-funded EpiC project | E-poster | PrEP |